Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug463 | Blood collection on admission and longitudinally Wiki | 1.00 |
drug3090 | Solution-Focused Support Program Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D001008 | Anxiety Disorders NIH | 0.23 |
D000077062 | Burnout, Psychological NIH | 0.16 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the physiopathological mechanisms underlying the clinical aggravation of COVID-19 patients remain misunderstood. The project aim is to create a prospective cohort of biological samples collected from well characterized COVID-19 patients. This project aims first to identify based on these samples an early immune signature predictive of clinical worsening of COVID-19 patients in order to improve their management, and secondarily to better understand pathophysiological mechanisms underlying the different phases of the disease in order to identify innovative therapeutic targets and vaccine perspectives.
Description: Analysis of the phenotypic profiling of blood T-cells by multicolor fluorescence-activated cell sorter (FACS) analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 0Description: Analysis on plasma samples of a wide range of cytokines and chemokines using multiplex
Measure: Dosage of cytokines and chemokines in plasma samples Time: Day 0Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 2Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 4Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 8Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 12Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 30 (or in discharge)Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 0Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 2Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 4Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 8Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 12Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 30 (or in discharge)Persons infected with Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2 vary in severity from being asymptomatic to having fever, cough, sore throat, general weakness and fatigue and muscular pain and in the most severe cases, severe pneumonia, acute respiratory distress syndrome and sepsis potentially leading to death. Predictive markers of clinical worsening after admission are lacking. COVID-19 immunopathogenesis and relevant therapeutic strategies are still under investigation. Although viral shedding peaks during the first week of symptoms, reports show that clinical deterioration often coincides with the development of host antiviral immune responses. The inflammatory response to SARS-CoV-2 infection may underpin COVID-19 pathogenesis leading to aberrant and excessive immune responses that may enter the pulmonary circulation in large numbers and play an immune damaging role causing lung functional disability resulting in clinical worsening. Therapeutic strategies using corticosteroids or biotherapies targeting IL-6 may be valuable in some patients. Based on a better understanding of COVID-19 immunopathogenesis, the identification of predictive biomarkers early in the disease process would be of outstanding interest to tailor prompt therapeutic interventions. On these bases, the present project aims to unravel, using innovative integrated multimodal immunological approaches, immunologic predictive markers by finely characterizing from their admission innate and adaptive immune responses in two well described cohorts of COVID-19 patients that are being collected in Toulouse (COVID-BioToul) and Bordeaux (COLCOV-19 BX).Those two biological cohorts are connected with two clinical cohorts in Toulouse and Bordeaux in order to have a very well defined population of COVID-19 patients and their clinical outcome. In both cohorts, investigators harvest and cryopreserve biological samples, including plasma and peripheral blood mononuclear cells (PBMCs), on admission and longitudinally from patients evolving or not toward severe forms of the disease in Bordeaux and Toulouse University Hospitals and will allow to investigate primary and secondary objectives. Moreover in the two centers, there are also two clinical outpatients cohorts of healthcare workers attending dedicated clinics in the frame of their surveillance medical program, which constitute groups of patients with benign forms of COVID-19.
Description: Immune signature will be compared between COVID-19 patients according to their clinical characteristics and outcome, together with SARS-CoV2 viral shedding (known for every patient in the cohort) on samples harvested on admission: a phenotypic profiling of blood T-cells by multicolor FACS analysis (using 30+ color panels analyzed by multiparametric flow cytometry) assessing T cell subsets (classical CD4 or CD8 T-cells as well as unconventional gdT-cells and regulatory T cells) through the expression of a wide range of surface and intracellular markers.
Measure: Immune signature on admission : phenotypic profile of blood T-cells Time: Day 0Description: Immune signature will be compared between COVID-19 patients according to their clinical characteristics and outcome, together with SARS-CoV2 viral shedding (known for every patient in the cohort) on samples harvested on admission: An analysis on plasma samples of concentration of a wide range of inflammatory cytokines such as IFNa, IFNb and IL-6.
Measure: Immune signature on admission : inflammatory cytokines Time: Day 0Description: On samples harvested longitudinally from patients, analysis of the relative magnitude and dynamic and polyfunctional profile of SARS-CoV-2 specific CD8 and CD4 T cell responses by analyzing the capacity of T cells to produce simultaneously a variety of cytokines such as IFNa, IFNb and IL-6, will be performed.
Measure: Dynamics of cellular immunity: CD4 and CD8 T cells Time: Day 0, Day 4, Day 8, Day 12, Day 30 (or in discharge)Description: On samples harvested longitudinally from patients, dynamics of gd T cells will be performed.
Measure: Dynamics of cellular immunity: gd T cells Time: Day 0, Day 4, Day 8, Day 12, Day 30 (or in discharge)Description: On samples harvested longitudinally from patients, transcriptomic analysis of different types of T cells will be performed.
Measure: Dynamics of cellular immunity: T cell transcriptomic analysis Time: Day 0, Day 4, Day 8, Day 12, Day 30 (or in discharge)Description: On samples harvested longitudinally from patients, humoral immunity will be performed.
Measure: Dynamics of cellular immunity: humoral immunity Time: Day 0, Day 4, Day 8, Day 12, Day 30 (or in discharge)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports